Application | Comment | Organism |
---|---|---|
drug development | Sirt5 is a potential drug target for the treatment of cancer, Alzheimer's disease, and Parkinson's disease | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
1-(2-(9H-pyrido[3,4-b]indol-9-yl)ethyl)-3-phenylurea | 10% inhibition at 0.1 mM | Homo sapiens | |
3-(((2-(9H-pyrido[3,4-b]indol-9-yl)ethyl)amino)methyl)benzoic acid | 32% inhibition at 0.1 mM | Homo sapiens | |
3-((2-(9H-pyrido[3,4-b]indol-9-yl)acetamido)methyl)benzoic acid | 21% inhibition at 0.1 mM | Homo sapiens | |
3-((2-(9H-pyrido[3,4-b]indol-9-yl)ethyl)carbamoyl)benzoicacid | 15% inhibition at 0.1 mM | Homo sapiens | |
3-(3-(2-(9H-pyrido[3,4-b]indol-9-yl)ethyl)ureido)benzoic acid | 36% inhibition at 0.1 mM | Homo sapiens | |
4-(((2-(9H-pyrido[3,4-b]indol-9-yl)ethyl)amino)methyl)benzoic acid | 22% inhibition at 0.1 mM | Homo sapiens | |
4-((2-(9H-pyrido[3,4-b]indol-9-yl)acetamido)methyl)benzoic acid | 25% inhibition at 0.1 mM | Homo sapiens | |
4-((2-(9H-pyrido[3,4-b]indol-9-yl)ethyl)carbamoyl)benzoic acid | 25% inhibition at 0.1 mM | Homo sapiens | |
4-(3-(2-(9H-pyrido[3,4-b]indol-9-yl)ethyl)ureido)benzoic acid | 52% inhibition at 0.1 mM | Homo sapiens | |
5-[[4-(benzyloxy)phenyl]methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione | - |
Homo sapiens | |
cambinol | - |
Homo sapiens | |
ethyl 4-[[2-(9H-pyrido[3,4-b]indol-9-yl)acetamido]methyl]benzoate | 12% inhibition at 0.1 mM | Homo sapiens | |
GW5074 | 85% inhibition at 0.1 mM | Homo sapiens | |
additional information | design and synthesis of 9-substituted norharmane derivatives as potential Sirt5 inhibitors, molceular docking, overview | Homo sapiens | |
N-(2-(9H-pyrido[3,4-b]indol-9-yl)ethyl)benzamide | 7% inhibition at 0.1 mM | Homo sapiens | |
N-(4-chlorobenzyl)-2-(9H-pyrido[3,4-b]indol-9-yl)acetamide | 18% inhibition at 0.1 mM | Homo sapiens | |
N-(pyridin-3-ylmethyl)-2-(9H-pyrido[3,4-b]indol-9-yl)acetamide | 24% inhibition at 0.1 mM | Homo sapiens | |
N-benzyl-2-(9H-pyrido[3,4-b]indol-9-yl)acetamide | 8% inhibition at 0.1 mM | Homo sapiens | |
N-benzyl-2-(9H-pyrido[3,4-b]indol-9-yl)ethan-1-amine | 10% inhibition at 0.1 mM | Homo sapiens | |
nicotinamide | - |
Homo sapiens | |
sirtinol | - |
Homo sapiens | |
suramin | - |
Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
mitochondrion | - |
Homo sapiens | 5739 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | Q9NXA8 | - |
- |
Synonyms | Comment | Organism |
---|---|---|
SIRT5 | - |
Homo sapiens |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.0126 | - |
pH and temperature not specified in the publication | Homo sapiens | 5-[[4-(benzyloxy)phenyl]methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione | |
0.0425 | - |
pH and temperature not specified in the publication | Homo sapiens | cambinol | |
0.0466 | - |
pH and temperature not specified in the publication | Homo sapiens | nicotinamide | |
0.0466 | - |
pH and temperature not specified in the publication | Homo sapiens | suramin | |
0.0489 | - |
pH and temperature not specified in the publication | Homo sapiens | sirtinol |
General Information | Comment | Organism |
---|---|---|
malfunction | because these modifications by Sirt5 cover a broad range of pivotal protein substrates involved in cellular metabolism and metabolic energy homeostasis, aberrant activity of Sirt5 is considered to be a very critical factor for many human diseases, for example, cancer, Alzheimer's disease, and Parkinson's disease | Homo sapiens |
physiological function | Sirt5 has only weak deacetylation, but has robust desuccinylation, demalonylation, and deglutarylation activities in vitro and in vivo. Modifications by Sirt5 cover a broad range of pivotal protein substrates involved in cellular metabolism and metabolic energy homeostasis | Homo sapiens |